|
|
Vaccine Detail
|
GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid KLH Conjugate Vaccine |
| Vaccine Information |
- Vaccine Name: GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid KLH Conjugate Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid (NCT01349647)
- Immunization Route: Other
- Description: This vaccine used to treat patients with small cell lung cancer by using several components (small cell lung cancer targets) that have been tested individually in patients with small cell lung cancer or other cancers (GD2, GD3, Globo H, Fucosyl GM1 and N-propionylated polysialic acid) so that the body will make antibodies to the vaccine which will also react against the cancer. Two other substances (KLH and OPT-821) are added which boost the immune system. (NCT01349647) Vaccination with the pentavalent KLH conjugate vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing any of these antigens. (NCIT_C97034)
|
| Host Response |
|
|
| References |
NCIT_C97034: Pentavalent KLH Conjugate Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C97034]
NCT01349647: Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid [https://clinicaltrials.gov/study/NCT01349647]
|
|
